Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 9/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 2/20 | 0.42 |
| ▸ | RXRB | P28702 | 2/20 | 0.42 |
| ▸ | RXRG | P48443 | 2/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1332605 | 0.85 | PTGDR2 (0.60) | PTGDR2 | |
| SCHEMBL5983726 | 0.82 | PTGDR2 (0.46) | PTGDR2HSD11B1 | |
| SCHEMBL1331604 | 0.78 | TOP2A (0.44) | PTGDR2HSD11B1 | |
| SCHEMBL2579113 | 0.78 | PPIA (0.46) | MRGPRX4RXRARXRBRXRGHTR2C | |
| SCHEMBL2111567 | 0.75 | PTGDR2 (0.72) | PTGDR2KEAP1NFE2L2RXRARXRB | |
| SCHEMBL24781012 | 0.75 | HTR2C (0.53) | MRGPRX4RXRARXRBRXRGHTR2C | |
| SCHEMBL4153374 | 0.73 | PTGDR2 (0.54) | PTGDR2 | |
| SCHEMBL2575323 | 0.73 | PTGER1 (0.48) | — | |
| SCHEMBL7365243 | 0.73 | NPC1 (0.47) | HTR2CSLC6A4HTR2B | |
| SCHEMBL2580807 | 0.72 | PPIA (0.47) | MRGPRX4RXRARXRBRXRGSLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394986-B2 | Phenoxiacetic acid derivatives | ASTRAZENECA AB (GB) | 2013-03-12 | — | — | US | disclosed |
| US-20110281898-A1 | PHENOXIACETIC ACID DERIVATIVES | ASTRAZENECA AB | 2011-11-17 | — | — | US | disclosed |
| US-8003703-B2 | Phenoxiacetic acid derivatives | ASTRAZENECA AB (SE) | 2011-08-23 | — | — | US | disclosed |
| EP-1660431-B1 | PHENOXYACETIC ACID DERIVATIVES | ASTRAZENECA AB (SE) | 2009-04-01 | — | — | EP | disclosed |
| US-20060293352-A1 | Phenoxiacetic acid derivatives | ASTRAZENECA AB (SE) | 2006-12-28 | — | — | US | disclosed |
| EP-1660431-A2 | PHENOXYACETIC ACID DERIVATIVES | Astrazeneca AB (SE) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005018529-A2 | PHENOXIACETIC ACID DERIVATIVES | ASTRAZENECA AB (SE) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293352-A1 | Phenoxiacetic acid derivatives | HRH2, HRH1, HCAR2 | MRGPRX4 49/4885PTGDR2 13/4885HSD11B1 1266/4885 |
| US-20110281898-A1 | PHENOXIACETIC ACID DERIVATIVES | HIF1A, HPD, HIF1AN | MRGPRX4 1800/4885PTGDR2 256/4885HSD11B1 1970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.